Korea Arlico Pharm Co.,Ltd. (KOSDAQ: 260660)

Market Cap	61.84B
Revenue (ttm)	178.83B
Net Income (ttm)	-8.86B
Shares Out	15.33M
EPS (ttm)	-677.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,687
Open	4,105.00
Previous Close	4,060.00
Day's Range	4,050.00 - 4,180.00
52-Week Range	3,835.00 - 6,550.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Korea Arlico Pharm Co.,Ltd.

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. w...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 112
• Stock Exchange: KOSDAQ
• Ticker Symbol: 260660

Financial Performance

In 2023, Korea Arlico Pharm Co.,Ltd.'s revenue was 187.15 billion, an increase of 11.58% compared to the previous year's 167.74 billion. Earnings were 3.06 billion, a decrease of -61.90%.